FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients
研究ライブラリに戻る

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

A new study initiated by Novo Nordisk A/S aims to evaluate how well patients adhere to and stay on their medication when using Ozempic (semaglutide) compared with other anti-diabetic drugs for treating type 2 diabetes mellitus (T2DM). This real-world research, listed under NCT07456774 on ClinicalTrials.gov, offers valuable insights into the effectiveness and patient compliance of semaglutide in managing T2DM in China.

Background

Type 2 diabetes is a chronic condition that affects millions of people worldwide. Effective management often involves long-term use of medications to control blood sugar levels and prevent complications such as heart attacks (MACE) and kidney damage. Semaglutide, the active ingredient in Ozempic, has shown promising results in clinical trials for improving glycemic control and reducing cardiovascular risks. However, there is a need to understand how patients respond to this treatment in real-world settings where adherence can be challenging.

The study's primary objective is to assess the incidence of major adverse cardiac events (MACE) and renal complications between Ozempic users and those on other anti-diabetic medications among adult T2DM patients. By comparing these outcomes, researchers hope to provide a clearer picture of semaglutide’s long-term benefits versus traditional treatments.

Key Details

This retrospective study is currently enrolling participants who have already been using either Ozempic or another form of antidiabetic medication. The research team will analyze medical records and patient data to track adherence rates, persistence with treatment, and health outcomes over time.

The inclusion criteria are broad, aiming to include a diverse group of T2DM patients across various age groups, genders, and ethnicities. This comprehensive approach is crucial for ensuring the study's findings can be generalized to different populations.

Novo Nordisk’s initiative underscores the growing importance of real-world evidence in evaluating drug efficacy and safety beyond what randomized controlled trials (RCTs) can provide. By focusing on adherence and persistence rates, this research addresses one of the critical challenges in diabetes management: patient compliance with prescribed treatments.

Key Takeaways

  • Comparative Analysis: The study will compare Ozempic users to those on other anti-diabetic drugs for better understanding of long-term benefits.
  • Patient Adherence: It aims to assess how well patients stick to their medication regimen over time, which is crucial for managing T2DM effectively.
  • Health Outcomes: Researchers will track major adverse cardiac events and renal complications as key indicators of treatment success.
  • Diverse Population: The study includes a wide range of patient demographics to ensure the results are applicable across different groups.

What This Means

For the peptide research community, this study highlights the importance of real-world evidence in evaluating new treatments like semaglutide. By understanding how patients interact with and benefit from these medications outside of controlled settings, researchers can provide more robust recommendations for clinical practice.

Moreover, the findings could influence future regulatory decisions by the FDA regarding peptide therapies. Demonstrating high adherence rates and positive health outcomes may lead to wider adoption of Ozempic in diabetes management protocols.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。